BHCNYSEPharmaceutical PreparationsFiscal year ends December 31
Bausch Health Companies Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$6.32+0.02 (+0.32%)
Close on Oct 19, 2026
- Market cap
- $2.39B
- P/E (TTM)
- –
- Dividend yield
- –
Bausch Health Companies Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch + Lomb | $1.39B | $1.24B | $1.41B | $1.28B | $1.28B | $1.14B | $1.28B | $1.20B | $1.22B | $1.10B | $1.17B | $1.01B | 48.9% | +9.1% |
| Salix | $758.00M | $639.00M | $693.00M | $716.00M | $627.00M | $542.00M | $634.00M | $642.00M | $558.00M | $499.00M | $583.00M | $614.00M | 26.6% | +20.9% |
| International | $305.00M | $285.00M | $306.00M | $286.00M | $278.00M | $262.00M | $279.00M | $291.00M | $276.00M | $265.00M | $290.00M | $275.00M | 10.7% | +9.7% |
| Diversified | $219.00M | $185.00M | $255.00M | $258.00M | $219.00M | $205.00M | $228.00M | $269.00M | $251.00M | $202.00M | $259.00M | $259.00M | 7.7% | 0.0% |
| Solta Medical | $176.00M | $171.00M | $137.00M | $140.00M | $128.00M | $113.00M | $138.00M | $112.00M | $102.00M | $88.00M | $103.00M | $83.00M | 6.2% | +37.5% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix | $605.00M | $468.00M | $529.00M | $570.00M | $455.00M | $371.00M | $460.00M | $436.00M | $377.00M | $329.00M | $419.00M | $429.00M | +33.0% |
| Bausch + Lomb | $335.00M | $277.00M | $396.00M | $301.00M | $248.00M | $180.00M | $309.00M | $283.00M | $274.00M | $242.00M | $281.00M | $244.00M | +35.1% |
| Diversified | $142.00M | $112.00M | $179.00M | $182.00M | $139.00M | $127.00M | $157.00M | $189.00M | $166.00M | $114.00M | $169.00M | $172.00M | +2.2% |
| Solta Medical | $91.00M | $75.00M | $55.00M | $70.00M | $54.00M | $53.00M | $73.00M | $53.00M | $47.00M | $40.00M | $47.00M | $33.00M | +68.5% |
| International | $90.00M | $88.00M | $81.00M | $90.00M | $78.00M | $85.00M | $98.00M | $105.00M | $86.00M | $87.00M | $99.00M | $91.00M | +15.4% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $2.83B | $2.50B | $2.77B | $2.66B | $2.50B | $2.23B | $2.53B | $2.48B | $2.38B | $2.13B | $2.38B | $2.21B | 99.1% | +12.8% |
| Other revenues | $27.00M | $24.00M | $28.00M | $24.00M | $26.00M | $32.00M | $31.00M | $28.00M | $24.00M | $24.00M | $26.00M | $25.00M | 0.9% | +3.8% |
| Price Appreciation Credit | $18.00M | $2.00M | $15.00M | $1.00M | $0 | $2.00M | $18.00M | $0 | $0 | $0 | $11.00M | $0 | 0.6% | – |
| Branded and Other generics | – | – | – | – | – | – | $233.00M | $245.00M | $258.00M | $245.00M | $229.00M | $263.00M | – | – |
| OTC | – | – | – | – | – | – | $505.00M | $472.00M | $490.00M | $437.00M | $484.00M | $457.00M | – | – |
| Devices | – | – | – | – | – | – | $614.00M | $567.00M | $547.00M | $512.00M | $528.00M | $494.00M | – | – |
| Pharmaceuticals | – | – | – | – | – | – | $1.18B | $1.20B | $1.09B | $935.00M | $1.14B | $999.00M | – | – |
| Other revenues | – | – | – | – | – | – | $31.00M | $28.00M | $23.00M | $24.00M | $26.00M | $25.00M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mexico | – | – | – | – | – | – | $67.00M | $88.00M | $84.00M | $76.00M | $88.00M | $90.00M | – | – |
| Canada | – | – | – | – | – | – | $109.00M | $104.00M | $99.00M | $90.00M | $98.00M | $92.00M | – | – |
| Poland | – | – | – | – | – | – | $94.00M | $92.00M | $78.00M | $86.00M | $87.00M | $82.00M | – | – |
| Russia | – | – | – | – | – | – | $44.00M | $42.00M | $39.00M | $36.00M | $43.00M | $35.00M | – | – |
| Japan | – | – | – | – | – | – | $52.00M | $46.00M | $47.00M | $43.00M | $49.00M | $47.00M | – | – |
| China | – | – | – | – | – | – | $145.00M | $132.00M | $122.00M | $97.00M | $126.00M | $113.00M | – | – |
| France | – | – | – | – | – | – | $52.00M | $52.00M | $65.00M | $61.00M | $45.00M | $49.00M | – | – |
| Germany | – | – | – | – | – | – | $34.00M | $40.00M | $41.00M | $44.00M | $33.00M | $34.00M | – | – |
| Other | – | – | – | – | – | – | $292.00M | $263.00M | $272.00M | $256.00M | $279.00M | $242.00M | – | – |
| U.S. | – | – | – | – | – | – | $1.54B | $1.54B | $1.44B | $1.25B | $1.46B | $1.36B | – | – |
| United Kingdom | – | – | – | – | – | – | $35.00M | $34.00M | $33.00M | $33.00M | $33.00M | $32.00M | – | – |
| Italy | – | – | – | – | – | – | $23.00M | $23.00M | $24.00M | $24.00M | $22.00M | $20.00M | – | – |
| South Korea | – | – | – | – | – | – | $44.00M | $38.00M | $34.00M | $30.00M | $24.00M | $24.00M | – | – |
| Spain | – | – | – | – | – | – | $28.00M | $21.00M | $27.00M | $23.00M | $25.00M | $20.00M | – | – |
From the segment and revenue-disaggregation notes of Bausch Health Companies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.